September 29, 2016 08:29 AM EDT
R&D

Step two: Cel­gene grabs a $20M op­tion, plots MS PhII for Abide’s cannabi­noid drug

John Carroll

Editor & Founder

San Diego-based Abide Ther­a­peu­tics is build­ing on about 5,000 years of hu­man his­to­ry re­gard­ing the med­i­c­i­nal as­pects of cannabis. The biotech be­lieves that its drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times